Business
FDA panel knocks down Pfizer, Lilly’s osteoarthritis pain drug in near-unanimous vote – FierceBiotech
After dozens of trials over more than 15 years, Pfizer and Eli Lilly’s osteoarthritis hopeful was poised for an FDA decision in December 2020—that is, until the…
After dozens of trials over more than 15 years, Pfizer and Eli Lillys osteoarthritis hopeful was poised for an FDA decision in December 2020that is, until the agency called a panel of outside experts to chew over the drugs application. That panel came down against the drug in a vote on Thursday because of major safety risks and an inadequate plan to manage them.
The Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted 19-1 that a drug safety strategy proposed…
-
Noosa News22 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane
-
General24 hours agoKen Hinkley has called time at the Power, but he’s the ‘proudest coach the world has seen’
-
Noosa News24 hours agoGovernment stands by funding rules barring youth justice organisations from speaking to media
-
General18 hours agoIndia to defend ‘red lines’ as fresh tariffs loom